Apoxis SA acquired by TopoTarget A/S
|
|
|
|
|
APO010: human FAS-ligand protein product generated via MegaLigand¢â proprietary protein technology platform in Phase I clinical trials; APO866: inhibits NAD+ production Phase II clinical trials | |
Korean Distributor : ??? |
Products information :
|
|
|
|
|
|
|
|
|
|